Adlai Nortye Gains Clearance to Launch First-in-Class Pan-RAS(ON) ADC Trial in Australia
ANL has more than doubled off its 52-week low of $0.879.
Summary
Adlai Nortye announced HREC approval and CTN submission to initiate a Phase I trial of AN4035, a first-in-class pan-RAS(ON) ADC, in Australia. The trial targets CEACAM5-enriched solid tumors, with dosing expected in H2 2026.
Key Events · Product Development and Regulatory · ANL
-
First-in-Class ADC Enters Clinic
AN4035, a CEACAM5-targeting pan-RAS(ON) ADC, has received HREC approval and CTN submission in Australia, making it the first pan-RAS(ON) ADC to enter clinical development globally.
-
Phase I Trial Design
The global Phase I trial will evaluate AN4035 as monotherapy and in combination with cetuximab in patients with CEACAM5-enriched, RAS-addicted solid tumors, including colorectal, pancreatic, and lung cancers.
-
Platform Validation
AN4035 is the first drug candidate to demonstrate proof-of-concept for the company's RASiCA platform, which conjugates a pan-RAS(ON) inhibitor to an antibody for targeted delivery.
-
Regulatory Expansion Underway
IND applications for AN4035 are being filed with the U.S. FDA and China NMPA, broadening the trial's geographic scope beyond Australia.
Analysis · ANL · Life Sciences
Adlai Nortye has received HREC approval and submitted a CTN to commence a Phase I trial for AN4035, a first-in-class pan-RAS(ON) ADC targeting CEACAM5-positive solid tumors. This milestone marks the first clinical validation of the company's RASiCA platform and broadens its pipeline beyond the oral pan-RAS inhibitor AN9025. The trial will assess AN4035 both as a monotherapy and in combination with cetuximab across colorectal, pancreatic, and lung cancers. Patient dosing is anticipated in the second half of 2026, while IND filings are also progressing in the U.S. and China. For a biotech with a $520M market cap, advancing a novel ADC into the clinic represents a significant de-risking event that could reshape the investment thesis if early data prove positive.
At the time of this filing, ANL was trading at $13.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $520M. The 52-week trading range was $0.88 to $17.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.